Unicycive Therapeautics, Inc., US90466Y1038

Unicycive Therapeautics, Inc., US90466Y1038

23.09.2022 - 15:14:57

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

a survey of nephrologists ? doctors who specialize in kidney health ? and found that their top concerns in managing hyperphosphatemia in their patients was the need for a lower pill burden and better patient compliance.

Many people suffering from hyperphosphatemia also have other comorbidities that require taking other pills, creating a high pill burden. This leads to 62% of patients self-reporting non-compliance ? patients neglecting to take their medication because they are overwhelmed by the number and size of the pills that they must take and their side effects.

The efficiency and smaller size of RenazorbTM pills may reduce the pill burden for these patients by 3 to 4 fold. Accordingly, nephrologists say they would prescribe RenazorbTM (once approved) to 34% of their dialysis patients requiring phosphate binder therapy - this is a market-leading figure indicative of the levels of practitioner confidence in the promise for this new drug.

Notably, Unicycive also recently signed an agreement with Lee?s Pharmaceutical (HK) Ltd., a subsidiary of Lee?s Pharmaceutical Holdings Ltd. (OTC: LPCUF), for exclusive distribution rights to RenazorbTM in China and other Asian markets.

The worldwide market for hyperphosphatemia drugs sits at over $2 billion (with over $1 bn of that being the U.S. market). It is expected to achieve a 5.3% compound annual growth rate between 2021 and 2028. Unicycive believes that this leaves the field wide open for a drug that will bring real solutions to patients suffering from inadequate and burdensome medicine for a persistent medical problem worldwide.

?We were delighted to initiate our pivotal bioequivalence trial of Renazorb(?), which keeps us on track to complete the study around year-end and to file a new drug application in 2023,? said Unicycive CEO Shalaba Gupta. He also said that the agreement with Lee?s Pharmaceutical ?underscores the potential for Renazorb(?) as a best-in-class phosphate binder worldwide.?

To learn more about the company, visit its website www.unicycive.com.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive?s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Anne Marie Fields - Stern Investor Relations

+1 212-362-1200

annemarie.fields@sternir.com

Company Website

https://unicycive.com/

News Source: News Direct

23.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Unicycive Therapeautics, Inc.

United States ISIN: US90466Y1038 EQS News ID: 1449205 ? End of News EQS News Service

1449205??23.09.2022?CET/CEST

@ dgap.de